semaglutide and tirzepatide. Semaglutide/Tirzepatide: Beyond Weight Loss: Shamsah Amersi, MD: OB-GYNs Switching from Semaglutide to Tirzepatide:

The act requires drugs to demonstrate safety and efficacy through an approved regulatory pathway before human use

The new research published in April 2026 showed improved blood pressure and cholesterol markers in participants, but a dedicated cardiovascular outcomes trial with hard endpoints is still in progress

Early Appetite and Satiety Conditioning: Helps the body adapt to delayed gastric emptying, gently introducing early portion control and healthy eating habits

This trial is designed to generate impactful data that demonstrates our ability to safely and efficiently deliver an oral GLP-1R agonist using a validated technology. Prof Carel le Roux References 1

Lundsgaard A-M, Fritzen AM, Kiens B